HER2 or EGFR Expressing Advanced Solid Malignancies Clinical Trial
Official title:
Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment